Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms

NCT03761017 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT03761017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03761017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2018
Completion date
January 27, 2025
Enrollment
162 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, colorectal cancer, cutaneous melanoma, prostate cancer metastatic, solid tumor, adult, squamous cell non small cell lung cancer